IGF-IEc expression is increased in secondary compared to primary foci in neuroendocrine neoplasms.

Alexandraki KI, Philippou A, Boutzios G, Theohari I, Koutsilieris M, Delladetsima IK, Kaltsas GA

Oncotarget8 Sept 2017Cited by 12 (Europe PMC)

PMID29108282PMCIDPMC5668015DOI10.18632/oncotarget.20743PepBankPUB-29108282

Summary

Different Insulin-like growth factor-I (IGF-I) mRNA transcripts are produced by alternative splicing and particularly the IGF-IEc isoform has been implicated in the development and/or progression of various types of cancer. In the present study, we examined the potential role of IGF-IEc expression as a new immunohistochemical marker of aggressiveness in neuroendocrine neoplasms (NENs). We utilized immunohistochemical analysis in tissue specimens of 47 patients with NENs, to evaluate the expression of IGF-IEc (%) and Ki-67 proliferation index (%). Specimens from patients with tumors of different tissue origin, of either primary or metastatic lesions and of different grade were examined. Cytoplasmic IGF-IEc staining was found in 23 specimens of NENs or NECs: 10 pancreatic, 4 small bowel, 3 gastric, 1 lung, 1 uterine and 4 poorly differentiated of unknown primary origin. Ki-67 and IGF-IEc expression was positively correlated in all the samples studied (r=0.31, p=0.03). IGF-1Ec expression was more prevalent in specimens originating from metastatic foci with high Ki-67 compared to primary sites with low Ki-67 expression (p=0.036). These findings suggest a possible role of IGF-IEc in NEN tumorigenesis and progression to metastases that could be used as an additional new marker of a more aggressive behavior and a potential drugable target.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In patients with neuroendocrine neoplasms, cytoplasmic IGF-IEc staining was found in 23 specimens.
In plain wordsIn 47 patients with neuroendocrine tumors, the body's own IGF-IEc was found in the cells of 23 tumor samples.
Peptide
MGF / PEG-MGF
Outcome
Not applicableCytoplasmic IGF-IEc staining in neuroendocrine neoplasms
Study
n = 47
Outcome group
Tumor growth · Cancer
Measurements
Specimens with cytoplasmic IGF-IEc staining
23 specimens
NENs or NECs
Source sentences
Summary
Cytoplasmic IGF-IEc staining was found in 23 specimens of NENs or NECs: 10 pancreatic, 4 small bowel, 3 gastric, 1 lung, 1 uterine and 4 poorly differentiated of unknown primary origin.
1 context sentence(design, population, supporting numbers)
Summary · context
We utilized immunohistochemical analysis in tissue specimens of 47 patients with NENs, to evaluate the expression of IGF-IEc (%) and Ki-67 proliferation index (%).
This result measures the body's own MGF / PEG-MGF. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-2910828201
02HumanEndogenous levelObservational studyOther
In patients with neuroendocrine neoplasms, IGF-IEc expression was positively correlated with Ki-67 expression.
In plain wordsIn patients with neuroendocrine tumors, higher natural IGF-IEc levels were linked to a higher tumor growth marker.
Peptide
MGF / PEG-MGF
Outcome
IncreaseCorrelation of IGF-IEc with Ki-67
Study
n = 47
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Ki-67 and IGF-IEc expression was positively correlated in all the samples studied (r=0.31, p=0.03).
1 context sentence(design, population, supporting numbers)
Summary · context
We utilized immunohistochemical analysis in tissue specimens of 47 patients with NENs, to evaluate the expression of IGF-IEc (%) and Ki-67 proliferation index (%).
This result measures the body's own MGF / PEG-MGF. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-2910828202
03HumanEndogenous levelObservational studyOther
In patients with neuroendocrine neoplasms, IGF-1Ec expression was more prevalent in metastatic foci with high Ki-67 than in primary sites with low Ki-67.
In plain wordsIn patients with neuroendocrine tumors, natural IGF-1Ec was more common in spread tumors than in primary tumors.
Peptide
MGF / PEG-MGF
Outcome
IncreaseIGF-IEc expression in metastatic versus primary foci
Study
n = 47
Comparator
Primary sites with low Ki-67
Outcome group
Tumor growth · Cancer
Source sentences
Summary
IGF-1Ec expression was more prevalent in specimens originating from metastatic foci with high Ki-67 compared to primary sites with low Ki-67 expression (p=0.036).
1 context sentence(design, population, supporting numbers)
Summary · context
We utilized immunohistochemical analysis in tissue specimens of 47 patients with NENs, to evaluate the expression of IGF-IEc (%) and Ki-67 proliferation index (%).
This result measures the body's own MGF / PEG-MGF. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-2910828203

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.